Committee on Energy and Commerce U.S. House of Representatives

Witness Disclosure Requirement – "Truth in Testimony" Required by House Rule XI, Clause 2(g)(5)

1.	Your Name:								
	Joanne Pike, DrPH								
2.	Your Title:								
	Alzheimer's Association, president and CEO								
	Alzheimer's Impact Movement, CEO								
3.	The Entity(ies) You are Representing:								
	Alzheimer's Association, Alzheimer's Impact Movement								
4.	Are you testifying on behalf of the Federal, or a State or local	Yes	No						
	government entity? (If "Yes," skip Item 5 and Item 6.)		X						
5.	Grants, Contracts, and Payments								
	a. Please list any <u>Federal grants or contracts</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2021</u> . Only grants, contracts, or payments related to the subject matter of the hearing must be listed. See attached.								
	 b. Please list any <u>contracts or payments originating with a foreign government</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2021</u>. Only grants, contracts, or payments related to the subject matter of the hearing 								
	must be listed.								
6.	Are you a fiduciary (i.e., authorized to act on behalf of or for the benefit	Yes	No						
	of) for any entity that has an interest in the subject matter of the hearing?								
7.	Please attach your curriculum vitae to your completed disclosure form.	1	1						

Joanne Pike

Signature:

Date: _____02/11/2024_____

NALZHEIMER'S® ASSOCIATION

Pharmaceutical Industry Contributions: FY23

This report is representative of annual cash contributions of \$10,000 and above.

Company	FY23	3 Contribution
Eisai	\$	758,473.00
Eli Lilly & Company	\$	696,613.00
Biogen	\$	430,000.00
Novo Nordisk	\$	350,000.00
Genentech / Roche	\$	330,000.00
Janssen / Johnson & Johnson	\$	181,874.10
Abbvie	\$	130,875.00
Prothena Biosciences	\$	119,500.00
Merck	\$	86,700.00
Takeda	\$	65,000.00
Novartis	\$	59,174.00
Athira Pharma	\$	55,000.00
Bracket Global	\$	55,000.00
Alzheon	\$	54,000.00
Cerveau Technologies	\$	54,000.00
Enigma Biomedical Group	\$	50,000.01
Acumen Pharmaceuticals	\$	50,000.00
Alector	\$	50,000.00
Cogstate	\$	50,000.00
Vaccinex	\$	50,000.00
WCG Clinical	\$	50,000.00
Acadia Pharmaceuticals	\$	35,000.00
PhRMA	\$	33,500.00
Sonora Quest Laboratories	\$	30,000.00
NeuroVision	\$	16,667.00
Lundbeck	\$	15,960.00
Progressive Medical Research	\$	15,000.00
Quanterix	\$	12,500.00
GE Healthcare	\$	10,000.00

Our Commitment to Transparency: The Alzheimer's Association[®] is dedicated to the transparent sharing of financial information, as well as information about our partnerships with companies, organizations and individuals. Learn more at alz.org/transparency.

This document is reviewed annually. Last updated Dec. 2023.



Biotech, Pharma, Diagnostics, Clinical Research Corporate Giving Summary

	\$ in		
	Total	Total \$ Category	Category as a % of
FY23	378.9	4.9	1.29%
FY22	425.1	4.5	1.06%
FY21	357.1	2.5	0.70%
FY20	360.9	3.2	0.89%
FY19	344.7	4.1	1.19%

Our Commitment to Transparency: The Alzheimer's Association[®] is dedicated to the transparent sharing of financial information, as well as information about our partnerships with companies, organizations and individuals. Learn more at alz.org/transparency.

This document is reviewed annually. Last updated Dec. 2023.

Alzheimer's Association

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS

Federal Agency grantor/program title	Federal CFDA number		FY21 Federal expenditures		FY22 Federal expenditures		FY23 Federal expenditures		TOTAL Federal spenditures
U.S. Department of Health and Human Services	number		xpenultures		expenditures		expenditures	e	kpenultures
Adminis ration f r Communi Li ing (AC)									
Services	93.043	\$	6,462	\$	-	\$	-	\$	6,462
Administration for Community Living (ACL) Special Programs for the Aging_Title III, Part B_Grants for									
Supportive Services and Senior Centers	93.044	\$	8,839	\$	105,798	\$	78,378	\$	193,015
Administration on Aging - Special Programs for the Aging - Title IV and Title II - Discretionary Projects Alzheimer s National Call									
Center - American Recovery & Reinvestment Act	93.048	\$	158,803	\$	252,561	\$	-	\$	411,364
Administration for Community Living - Alzheimer's Disease									
Demonstration Grants to States	93.051	\$	209,489	Ş	57,241	Ş	2,705	\$	269,435
Administration for Community Living - National Family Caregiver									
Caregiver Support, Title III, Part E	93.052	\$	2,344,934	Ś	2,949,082	Ś	2,419,659	Ś	7,713,675
						·	,		, .,
Administration for Community Living (ACL)									
Alzheimer s Disease Program Initiative (ADPI)	93.470	\$	1,375,698	\$	1,269,261	\$	1,221,654	\$	3,866,613
Administration for Children and Families (ACF) Social Services Block Grant	93.667		6226 217 00		¢100 070 00	÷		\$	502,395
Social Services Block Grant	93.007		\$336,317.00		\$166,078.00	Ş	-	Ş	502,395
Alzheimer's Disease Inititative: Specialized Supportive Services									
Project (ADI-SSS) thru Prevention and Public Health Funds (PPHF)	93.763	\$	124,178	\$	92,605	\$	-	\$	216,783
Centers for Medicaid & Medicare Services (CMS)									
State Survey and Certification of Health Care Providers and Suppliers (Title XVIII) Medicare	93.777	\$	-	\$	-	\$	7,550	\$	7,550
Administration for Community Living (ACL)									
Medicaid Cluster (Title XIX)	93.778	Ś	106,769	\$	194,866	\$	-	\$	301,635
Centers for Disease Control and Prevention - The Healthy Brain									
Initiative: Technical Assistance to Implement Public Health									
Actions related to Cognitive Health, Cognitive Impairment, and	93.334	ć	1 252 220	ć	2 202 062	÷	2 000 700	ć	7,522,061
Caregiving at the State and Local Levels	95.554	\$	1,352,238	Ş	2,283,063	Ş	3,886,760	\$	7,522,001
Activities to Support State, Tribal, Local and Territorial (STLT)									
Health Department Response to Public Health or Healthcare Crises	93.391	\$	-	\$	32,925	\$	84,211	\$	117,136
National Institutes of Health (NIH)									
Aging Research	93.866	\$	254,668	\$	727,349	Ş	1,002,398	\$	1,984,415
Health Resources and Services Administration (HRSA)									
Geriatric Workforce Enhancement Program GWEP Geriatric Education Centers GECs	93.969	Ś	244,893	\$	198,392	Ś	173,107	\$	616,392
·····		- <u>-</u>	,						
Total U.S. Department of Health and Human Services		\$	6,523,288	\$	8,329,221	\$	8,876,422	\$	23,728,931
United States Department of Justice (DOJ) Office for Victims of Crime									
Pass through: Northridge Hospital Foundation	16.582	\$	12,000	Ś	2,500	Ś	2,500	Ś	17,000
	10.502	Ŷ	12,000	Ŷ	2,000	Ŷ	2,550	7	_,,000
United States Department of Treasury (DOT)									
COVID-19 Coronavirus Relief Fund	21.019	\$	109,768	\$	-	\$	-	\$	109,768
American Rescue Plan Act / Coronavirus State and Local Fiscal Recovery Fund	21.027	\$	-	\$	-	\$	33,435	Ş	33,435
Total expenditures of federal awards		\$	6,645,056	Ś	8,331,721	Ś	8,912,357	Ś	23,889,134
i otal experiatures un reactal awaras		,	0,043,030	Ý	0,331,721	Ý	0,312,337	4	23,003,134

Alzheimer's Impact Movement

Pharmaceutical Industry Contributions: FY23

This report is representative of annual contributions over \$10,000

Company	FY23 C	FY23 Contribution			
Eisai	\$	50,000.00			
Eli Lilly & Company	\$	50,000.00			
Biogen	\$	25,000.00			
Genentech	\$	25,000.00			
Lundbeck	\$	25,000.00			
Novo Nordisk	\$	25,000.00			
PhRMA	\$	25,000.00			

Updated: 2/2024

Alzheimer's Impact Movement

Biotech, Pharma, Diagnostics, Clinical Research Corporate Giving Summary

	\$ in t	nousands	
		Total \$ Category	Category as a % of
	Total Revenue	(Bio, Pharma etc.)	Total Revenue
FY23	10,419	225	2.16%
FY22	10,561	375	3.55%
FY21	7,087	80	1.13%
FY20	<mark>6,303</mark>	125	1.98%
FY19	7,505	245	3.26%

Updated: 2/2024